Antisense technology for cancer therapy: does it make sense?
about
The upstream open reading frame mediates constitutive effects on translation of cytochrome p-450c27 from the seventh in-frame AUG codon in rat liverTerpene-loaded Liposomes and Isopropyl Myristate as Chemical Permeation Enhancers Toward Liposomal Gene Delivery in Lung Cancer cells; A Comparative StudyA monoclonal antibody extends the half-life of an anti-HIV oligodeoxynucleotide and targets it to CD4+ cells.erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.Hyperstable U1snRNA complementary to the K-ras transcripts induces cell death in pancreatic cancer cells.Oligodeoxynucleotide-based therapeutics for human leukemias.Antisense therapeutics in haematological malignancies.Molecular biology primer for the pediatric pathologist.Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.Future therapies for the treatment of bladder neoplasms.Recent status of the antisense oligonucleotide approaches in oncology.Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.Gene therapy for cancers.Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study.Preparation and in-vitro Evaluation of an Antisense-containing Cationic Liposome against Non-small Cell Lung Cancer: a Comparative Preparation Study.Effects of antisense oligodeoxynucleotide to type I collagen gene on hypertrophic scars in the transplanted nude mouse model.Attenuation of alpha1 collagen production with antisense ribonucleic acid in cultured hypertrophic scar fibroblasts.
P2860
Q28568176-8EC4B0A2-9954-404B-9488-FDBF072ABCE3Q28817640-2A45CBAC-B2F3-4863-BA81-19E31C5EC175Q34780339-6108D502-952D-4B0B-828C-AA14BF0AB289Q36080272-1DAA3047-BE79-471C-957D-99E3AD9C0B7CQ36646133-70F4A536-A511-49B4-9149-3516C1C2F228Q40386084-21178071-2B4F-4633-8A11-0F6FC0D40165Q40651224-A96712B7-9D0C-41A0-885C-D361D18FEF2AQ40659585-1C5A92B1-BF57-4585-B360-CB495E3F82A9Q40770171-A0AC8769-F762-40BC-8EAA-6B988AFBACB7Q40883449-802FE3AB-2D1C-4B70-8120-2EE0331F1369Q41061872-FBEBF6DC-0A05-43AD-BA97-CB436C068C4AQ41475501-B29E3690-B99B-4316-B559-75F325ED4724Q41883356-6218A660-E472-4010-BC94-62C2EA20F38CQ42122076-31435972-656B-486F-AEDA-AFA3F3E1F28AQ42789464-949B8979-408B-4AF2-99F7-612039B14C2BQ42927324-0227092A-8936-4C7D-B3E6-0125F5F783F9Q47725692-7595FEBE-D0ED-43F2-B08B-148A6FA17850Q47851097-CC77880A-31C3-4516-9F48-F44C6A79E70B
P2860
Antisense technology for cancer therapy: does it make sense?
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Antisense technology for cancer therapy: does it make sense?
@en
type
label
Antisense technology for cancer therapy: does it make sense?
@en
prefLabel
Antisense technology for cancer therapy: does it make sense?
@en
P2860
P356
P1476
Antisense technology for cancer therapy: does it make sense?
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1993.164
P407
P577
1993-05-01T00:00:00Z
P5875
P6179
1038643324